903 F.3d 1265
Fed. Cir.2018Background
- Orexo owns U.S. Patent No. 8,940,330 claiming a sublingual tablet (Zubsolv) with buprenorphine microparticles adhered to citric-acid carrier particles plus naloxone (4:1) and disintegrant; clinical data showed ~66% increased buprenorphine bioavailability and ability to reduce buprenorphine dose by ~29% versus Suboxone.
- Actavis filed an ANDA with a Paragraph IV certification seeking to market a generic Zubsolv, prompting Hatch–Waxman litigation; the district court found claims 1, 3–6, and 8–10 of the ’330 patent obvious and invalid.
- Prior art included Suboxone/Subutex tablets (homogeneous granulation containing citric acid but not as carrier particles), a buprenorphine/naloxone oral film patent that used citric acid to lower pH, Orexo’s earlier ’443 application (discloses active-on-carrier particle concept but not citric acid as carrier), and a general European application listing many water‑soluble carriers (not citric acid for this use).
- The district court concluded a person of ordinary skill would have been motivated to combine these references and would not have excluded citric acid as a carrier, discounting some objective indicia of nonobviousness as insufficient.
- On appeal, the Federal Circuit reversed, holding Actavis did not prove obviousness by clear and convincing evidence: the prior art did not teach or suggest using citric acid as carrier particles for micronized buprenorphine nor predict the unexpected improvements (bioavailability and reduced abuse) achieved by the claimed formulation.
Issues
| Issue | Orexo's Argument | Actavis's Argument | Held |
|---|---|---|---|
| 1. Whether the claimed formulation is obvious over prior art combinations | Prior art does not teach citric acid as carrier particles or the specific combination; clinical results were unexpected and merited nonobviousness | Prior art components (interactive mixtures, citric acid in Suboxone/film, carrier-particle concepts) would motivate a skilled artisan to combine them | Reversed: Actavis failed to prove obviousness by clear and convincing evidence; prior art did not suggest selecting and combining elements as claimed |
| 2. Whether there was a teaching/suggestion to use citric acid as a carrier particle | No reference teaches or suggests citric acid as carrier particles; concession at oral argument that no prior art shows that use | Citric acid was present in prior products and would have been an obvious choice as a carrier (expert testimony) | Held for Orexo: mere presence of citric acid in prior art and expert conjecture is hindsight; record lacks a teaching or suggestion to use it as carrier |
| 3. Role of objective indicia (unexpected results, long‑felt need, copying) | The 66% bioavailability increase, reduced dose, and less susceptibility to abuse are strong evidence of nonobviousness | Improved bioavailability is a difference of degree; prior art sought similar improvements so objective indicia are weak | Court found objective indicia probative and that the district court undervalued unexpected results; supports nonobviousness |
| 4. Standard of proof and hindsight risk in obviousness analysis | The challenger must show obviousness by clear and convincing evidence and avoid hindsight; the prior art must suggest the claimed selection/combination | District court applied prior-art teachings to conclude obviousness | Federal Circuit reversed district court's legal conclusion, holding the clear-and-convincing standard was not met and cautioning against hindsight-based reasoning |
Key Cases Cited
- Graham v. John Deere Co., 383 U.S. 1 (1966) (sets the Graham factual framework for obviousness)
- KSR Int’l Co. v. Teleflex Inc., 550 U.S. 398 (2007) (warns against hindsight and endorses flexible analysis of motivation to combine)
- In re Cyclobenzaprine Hydrochloride Extended-Release Capsule Patent Litig., 676 F.3d 1063 (Fed. Cir. 2012) (standard of review for bench trial obviousness determinations)
- InTouch Techs., Inc. v. VGO Commc’ns, Inc., 751 F.3d 1327 (Fed. Cir. 2014) (patentee challenging obviousness must show reasonable expectation of success)
- Leo Pharm. Prods., Ltd. v. Rea, 726 F.3d 1346 (Fed. Cir. 2013) (objective indicia are part of the overall obviousness analysis)
- In re Gordon, 733 F.2d 900 (Fed. Cir. 1984) (mere possibility of modification insufficient; prior art must suggest desirability of modification)
- Interconnect Planning Corp. v. Feil, 774 F.2d 1132 (Fed. Cir. 1985) (invention must be viewed from perspective of person of ordinary skill to avoid using inventor's blueprint)